Primary Hyperoxaluria Type 1 Clinical Trial
Official title:
Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3
Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3.
A multicenter randomized, double-blind, placebo-controlled phase 3 study The study is designed to compare the efficacy of stiripentol to a placebo in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3. The study will be conducted in 2 periods: a 6-month, placebo-controlled, double-blind treatment period (period 1) followed by a 6-month open-label treatment period with blind maintained on results (period 2). Patients who benefit from the treatment after the first 12 months of study treatment will be proposed to enter the open-label extension (OLE) part of the study to continue to assess the long-term efficacy and safety of stiripentol. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Completed |
NCT02830009 -
IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA
|
N/A | |
| Terminated |
NCT02795325 -
A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
|
Phase 1 | |
| Completed |
NCT03067142 -
Proteomics of Primary Hyperoxaluria Type 1
|
||
| Active, not recruiting |
NCT04152200 -
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
|
Phase 3 | |
| Recruiting |
NCT05001269 -
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
|
Phase 2 | |
| Recruiting |
NCT04982393 -
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
|
||
| Recruiting |
NCT04580420 -
Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD
|
Phase 2 |